HAART Helps Prevent HIV Transmission Among Individuals, Reducing HIV Diagnoses in the Community
Vancouver, BC (July 18, 2010) – The BC Centre of Excellence in HIV/AIDS (BC-CfE) published an important study today in the globally respected Lancet medical journal. The study strongly reinforces the view that the benefits of highly active antiretroviral therapy (HAART) extend beyond treatment of the virus to significantly preventing the transmission and spread of HIV.
Recognized as the gold standard treatment for HIV, HAART uses a combination of drugs to stop HIV from progressing to AIDS, extends life expectancy, and significantly reduces HIV-related deaths in diagnosed individuals.
“The expansion of HAART treatment plays an important role in the health of British Columbians with HIV, preventing HIV transmission and maximizing public health resources,” said Gordon Campbell, Premier of British Columbia.”Based on HAART’s effectiveness and ongoing research at the BC-CfE, Canada’s leading HIV/AIDS organization, the government of B.C. is investing in improving access to HAART through innovative programs such as the Seek and Treat initiative.”
The new study, funded by the U.S. National Institute on Drug Abuse (NIDA), found that increased levels of HAART treatment were associated with a decrease in community viral load and in new HIV diagnoses across British Columbia, particularly in populations with a history of injection drug use.
“These study results reinforce the effectiveness of HAART in preventing transmission of HIV, and support extending the treatment as prevention model developed at the BC-CfE and now being rolled out in major centres in Canada, the U.S. and elsewhere,” said Dr. Julio Montaner, study lead author and BC-CfE director. Montaner is also a professor and chair in AIDS research at the University of British Columbia and President of the International AIDS Society (IAS).
“This BC-CfE study suggests expanded HAART coverage may curb the spread of HIV,” said NIDA Director Dr. Nora D. Volkow.”These findings are especially important when it comes to populations with a history of injection drug use, as we now have a tool to help reduce the spread of HIV among them.”
Results of mathematical models have varied dramatically in their estimation of the potential impact of increased HAART coverage on HIV transmission, predicting anywhere from elimination to potential worsening of the HIV epidemic. Therefore, the present study was conducted to analyze, at the population level, the potential association between the expansion of HAART, viral load and new HIV diagnoses per year in a Canadian province with free access to HIV care. The population was then stratified for injection drug use status.
Data resulting from BC-CfE research showed that the number of individuals actively receiving HAART had a strong impact on overall viral load and new diagnoses in the community. As HAART coverage increased, new HIV diagnoses decreased; as HAART coverage stabilized, so too did viral load and new HIV diagnoses.
The expansion of HAART is proving to be an important prevention tool that complements efforts of community prevention programs in B.C. – programs working to educate people about HIV and deliver needle-exchange and harm reduction supplies for at-risk populations.
The study results align with the emphasis global leaders in HIV research, policy and advocacy place on early treatment to prevent transmission of HIV. Michel Sidibé, Executive Director of UNAIDS, the Joint United Nations Programme on HIV/AIDS, noted that treatment is a smart health investment, as it reduces HIV transmission, TB infection and maternal and child mortality within communities, and improves work productivity.
“The most recent evidence presented by the BC Centre for Excellence in HIV/AIDS and other leading research organizations supports these facts and tells us that we need to introduce treatment earlier,” said Sidibé.”Treatment not only saves lives, it can be one of the most compelling prevention tools we have.”
The B.C. government recently invested in a $48-million, four-year pilot project to provide HAART treatment to people in medical need, living with HIV, but not currently accessing the health system in Prince George and Vancouver. The program, called Seek and Treat, will improve access to HIV/AIDS medications among hard-to-reach populations in these two communities such as sex trade workers, injection drug users and men who have sex with men. The pilot is currently being evaluated as part of the BC-CfE’s innovative research program, Seek and Treat for the Optimal Prevention of HIV/AIDS (STOP HIV/AIDS¨).
Currently, more than 33 million people worldwide are infected with HIV, at least 7,400 people become infected with HIV each day and nearly 5,500 die daily from an AIDS-related illness.
For further statistics on the prevalence of HIV/AIDS in Canada and a full copy of the study, entitled Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study, please visit http://www.bccfe.ca/publications/expanded-haart-coverage.
The study was supported by NIDA’s annual Avant-Garde Award, which is intended to stimulate high-impact research that may lead to groundbreaking opportunities for the prevention and treatment of HIV/AIDS in drug abusers. Information on NIDA’s Avant-Garde program can be found at http://www.drugabuse.gov/about/organization/arp/avgp.htm.
-30-
About the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE)
The B.C. Centre for Excellence in HIV/AIDS (BC-CfE) is Canada’s largest HIV/AIDS research, treatment and education facility and is internationally recognized as an innovative world leader in combating HIV/AIDS and related diseases. Based at St. Paul’s Hospital, Providence Health Care, a teaching hospital of the University of British Columbia, the BC-CfE is dedicated to improving the health of British Columbians with HIV through developing, monitoring and disseminating comprehensive research and treatment programs for HIV and related illnesses.
About UBC
The University of British Columbia is one of Canada’s largest and most prestigious public research and teaching institutions. UBC is consistently ranked among the world’s 40 best universities, one of only two Canadian universities in this category. UBC consistently attracts more than $450 million per year in research funding from government, non-profit organizations and industry through 7,000 grants.
It is ranked within the top 10 North American universities in terms of the number of U.S. life sciences patents and the quality of activity generated from those patents, including spin-off company creation.
About the National Institute on Drug Abuse
The National Institute on Drug Abuse is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. The Institute carries out a large variety of programs to inform policy and improve practice. Fact sheets on the health effects of drugs of abuse and information on NIDA research and other activities can be found on the NIDA home page at www.drugabuse.gov. To order publications in English or Spanish, call NIDA’s new DrugPubs research dissemination center at 1-877-NIDA-NIH or 240-645-0228 (TDD) or fax or email requests to 240-645-0227 or drugpubs@nida.nih.gov. Online ordering is available at http://drugpubs.drugabuse.gov. NIDA’s new media guide can be found at http://drugabuse.gov/mediaguide.
The National Institutes of Health (NIH) — The Nation’s Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary Federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
For additional information or to request an interview, please contact:
Mahafrine Petigara
Edelman (for BC-CfE)
604-623-3007 ext. 297
mahafrine.petigara@edelman.com